Replies to post #795561 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

It’s becoming clearer that NWBO has not been idle since they submitted MAA. If you re-read the Feb 6, 2024 PR, it’s obvious they’ve been working through the regulatory pathway for Flaskworks approval behind the scenes.

“As soon as the GMP-grade units are delivered, Advent BioServices will undertake final qualification and validation of the GMP units and use engineering runs with the system to collect data in order to submit an application to regulators to approve the use of the system for production of DCVax-L.”

That line alone tells you that Advent (not Flaskworks directly) was the entity responsible for submitting Flaskworks validation data to the MHRA.
So, from Feb 2024 onward, NWBO’s key task was to get that closed automated system qualified under Advent’s GMP license. That’s a regulatory process, not an engineering one and it easily explains the extended timeline.

Fast-forward to Oct 24, 2025, when NWBO announced the acquisition of Advent.
The language in that PR isn’t random corporate fluff it’s practically regulatory housekeeping:

“The Company anticipates that this acquisition will help enable efficiencies and scale-up of operations...
Closing of operations at the GMP facility in London and reallocation of resources to the Sawston, UK facility...
Facilitating scale-up of manufacturing capacity... Streamlining and efficiencies in interactions with clinical sites and distribution of DCVax products.”

The MHRA requires a single accountable manufacturer for GMP oversight under UK ATMP rules. As long as Advent was a contractor, MHRA would have had to evaluate the entire subcontract chain, which would have slowed or even blocked approval of a closed automated system like Flaskworks.

The cleanest path was obvious: make Advent a wholly owned subsidiary. That consolidates IP, QA oversight, and GMP authority under one corporate umbrella. In other words, it’s very likely that MHRA made this integration a prerequisite before final sign-off on Flaskworks within the DCVax-L manufacturing license.

That also answers another question some keep asking: “Why hasn’t NWBO filed the NICE submission yet?” Because NICE can’t review cost-effectiveness or real-world rollout until the approved manufacturing process is locked. If Flaskworks is the production platform going forward, then its validation had to precede any NICE pricing and reimbursement process. Filing before that would have been premature.

This all fits the sequence you’d expect if MHRA and NWBO are finalizing a platform-level approval DCVax-L as the pilot case for autologous DC vaccines manufactured via Flaskworks. All evidence points to regulatory alignment, not inertia.

If this were to come to pass, I would value NWBO at $ 5B to $8B market cap